Get the Stockscreener App
392.56
0.59%
2.30
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $392.56, with a volume of 2.88M.
It is up +0.59% in the last 24 hours and down -4.73% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
See More
Previous Close:
$390.26
Open:
$390.26
24h Volume:
2.88M
Relative Volume:
1.13
Market Cap:
$156.49B
Revenue:
$42.90B
Net Income/Loss:
$6.52B
P/E Ratio:
23.02
EPS:
17.05
Net Cash Flow:
$6.72B
1W Performance:
-5.44%
1M Performance:
-4.73%
6M Performance:
-23.95%
1Y Performance:
-31.03%
1-Day Range:
$385.46
$395.78
1-Week Range:
$385.46
$416.81
52-Week Range:
$385.46
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
392.56 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
194.44 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
519.85 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.52 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
154.61 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Hyderabad-based CCMB, Thermo Fisher Scientific launch supply centre, aims at strengthening research in life sciences - Telangana Today
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MSN
Thermo Fisher’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Thermo Fisher stock hits 52-week low at $390.45 - Investing.com
Thermo Fisher stock hits 52-week low at $390.45 By Investing.com - Investing.com South Africa
Thermo Fisher Scientific’s SWOT analysis: stock outlook amid acquisitions, tariffs - Investing.com
Thermo Fisher Scientific Unveils New Mass Spectrometers to Advance Scientific Discovery - Insider Monkey
Thermo Fisher Scientific introduces the next generation Thermo Scientific™ Vanquish™ Charged Aerosol Detector P Series for more sensitive detection of impurities - bio-itworld.com
Thermo Fisher Scientific (TMO) Opinions on Diagnostics Division Sale - Nasdaq
Thermo Fisher Scientific Could Divest Diagnostics Division for More than $4B - Medical Device and Diagnostic industry
Flow Cytometer | Thermo Fisher Scientific Inc. | Jun 2025 - Photonics Spectra
Thermo Fisher Scientific Awarded $94M Navy Occupational Dosimetry System Contract - ExecutiveBiz
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific’s Accelerator™ Drug Development 360° CDMO and CRO Solutions - Business Wire
Ethris and Thermo Fisher partner on mRNA solutions - Yahoo Finance
Bioreactor Market Insights 2025-2033 | Leading Vendors: Thermo Fisher Scientific, GE Healthcare, Sartorius - openPR.com
Thermo Fisher (TMO) Eyes Future Growth with Strategic mRNA Deal and Acquisition - Daily Chhattisgarh News
Next-Gen Diagnostics Drive Biochips Market Growth: Thermo Fisher, Illumina, and PerkinElmer at the Forefront - openPR.com
Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business - PYMNTS.com
Thermo Fisher Scientific Explores Diagnostics Exit Amid mRNA Expansion S&P 500 - Kalkine Media
Thermo Fisher Scientific (NYSE:TMO) Explores US$4 Billion Diagnostics Sale, Expands mRNA Collaboration - simplywall.st
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition - MSN
Ethris and Thermo Fisher Partner to Streamline mRNA Therapeutics Development - BioPharm International
October 17th Options Now Available For Thermo Fisher Scientific (TMO) - Nasdaq
High Frequency Electrocautery Market Deep Research Report with - openPR.com
Deals of the day-Mergers and acquisitions - marketscreener.com
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms - Business Wire
Thermo Fisher said to weigh sale of some diagnostic assets for $4B - MSN
Thermo Fisher (TMO) Plans $4 Billion Sale of Diagnostics Divisio - GuruFocus
Thermo Fisher (TMO) Considers $4B Sale of Diagnostic Assets - GuruFocus
Thermo Fisher Reportedly Plans to Sell Parts of Diagnostics Unit for $4 Billion - marketscreener.com
Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports - ET HealthWorld
Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports By Reuters - Investing.com
Thermo Fisher Plans to Sell Parts of Diagnostics Unit for $4 Billion, FT Reports - US News Money
Thermo Fisher aims to sell parts of its diagnostics business for $4 billion, FT reports - TradingView
Thermo Fisher aims to sell parts of its diagnostics business for $4bn - Financial Times
Thermo Fisher (TMO) Stock Shows Signs of Rebound After Challenging Year - Daily Chhattisgarh News
Plasmid Purification Market Exclusive Report with Detailed - openPR.com
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples - Business Wire
APJ, EEMEA and LATAM Thermo Scientific AST plate guide - SelectScience
Brain Cancer Diagnostics Market Key Players AnalysisThermo - openPR.com
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Thermo Fisher (TMO) Closes with Minor Gains After Volatile Session, Stock Still Down Significantly for the Year - Daily Chhattisgarh News
Ex-Dividend Reminder: Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq
HSBC Adjusts Price Target on Thermo Fisher Scientific to $560 From $590 - marketscreener.com
Thermo Fisher Scientific highlights case for combining electron microscopy and microtomography - Metal Additive Manufacturing magazine
Thermo Fisher (TMO) Rallies Over 1%, But Still Faces Long-Term Headwinds - Daily Chhattisgarh News
$100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth This Much Today - Benzinga
Thermo Scientific Precis Methods - SelectScience
Thermo Scientific SureTect automation workflow - SelectScience
Thermo Fisher Cuts Annual Profit Outlook Amid Estimated $400M Tariff Hit - insights.citeline.com
Old National Bancorp Reduces Stake in Thermo Fisher Scientific - Zenopa
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):